HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function

Mitani, Yosuke; Ohashi, Shinya; Kikuchi, Osamu; Nakai, Yukie; Ida, Tomomi; Mizumoto, Ayaka; Yamamoto, Yoshihiro; Saito, Tomoki; Kataoka, Shigeki; Matsubara, Junichi; Yamada, Atsushi; Kanai, Masashi; Matsumoto, Shigemi; Sakai, Hiroaki; Yoshikawa, Kiyotsugu; Nakamura, Eijiro; Muto, Manabu

doi:10.1038/s41598-022-13189-y

Download PDF

Article
Open access
Published: 02 June 2022

HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function

Yosuke Mitani¹,
Shinya Ohashi¹,
Osamu Kikuchi¹,
Yukie Nakai¹,
Tomomi Ida¹,
Ayaka Mizumoto¹,
Yoshihiro Yamamoto¹,
Tomoki Saito¹,
Shigeki Kataoka¹,
Junichi Matsubara¹,
Atsushi Yamada¹,
Masashi Kanai¹,
Shigemi Matsumoto¹,
Hiroaki Sakai²,
Kiyotsugu Yoshikawa³,
Eijiro Nakamura⁴ &
…
Manabu Muto¹

Scientific Reports volume 12, Article number: 9213 (2022) Cite this article

1490 Accesses
3 Citations
2 Altmetric
Metrics details

Subjects

Abstract

Clinical cancer genome sequencing detects oncogenic variants that are potential targets for cancer treatment, but it also detects variants of unknown significance. These variants may interact with each other to influence tumor pathophysiology, however, such interactions have not been fully elucidated. Additionally, the effect of target therapy for those variants also unclarified. In this study, we investigated the biological functions of a HER2 mutation (G776S mutation) of unknown pathological significance, which was detected together with APC mutation by cancer genome sequencing of samples from a colorectal cancer (CRC) patient. Transfection of the HER2 G776S mutation alone slightly increased the kinase activity and phosphorylation of HER2 protein, but did not activate HER2 downstream signaling or alter the cell phenotype. On the other hand, the HER2 G776S mutation was shown to have strong oncogenic potential when loss of APC function was accompanied. We revealed that loss of APC function increased Wnt pathway activity but also increased RAS–GTP, which increased ERK phosphorylation triggered by HER2 G776S transfection. In addition, afatinib, a pan-HER tyrosine kinase inhibitor, suppressed tumor growth in xenografts derived from HER2 G776S-transfected CRC cells. These findings suggest that this HER2 mutation in CRC may be a potential therapeutic target.

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Article Open access 14 May 2024

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Article Open access 01 March 2023

Disentangling oncogenic amplicons in esophageal adenocarcinoma

Article Open access 14 May 2024

Introduction

In recent years, the development of next-generation sequencing (NGS) has enabled the detailed analysis of the cancer genome in cancer patients, and targeting of oncogenic driver alterations has been shown to be effective in several types of cancers^1,2,3,4. One of the possible targets among oncogenic driver alterations is the human epidermal growth factor receptor 2 (HER2)^5,6, also known as ERBB2, which is a member of the epidermal growth factor receptor (EGFR) family of homologous transmembrane receptor tyrosine kinases⁷. HER2-targeted therapies have improved outcomes for cancer patients with HER2 gene amplification and overexpression^8,9. Somatic point mutations in HER2 can also be detected by NGS in a number of cancers^10,11. Several major HER2 mutations, such as V777L in breast cancer¹² and HER2 exon 20 insertion mutations in lung cancer¹³, have been shown to be driver mutations that promote oncogenicity through constant phosphorylation of HER2 and are expected to be therapeutic targets.

In colorectal cancer (CRC), somatic point mutations in HER2 are detected in 4–6% of cases^6,14, most of which are diverse single nucleotide variants^6,10. V777L and V842I are the well-known mutations in CRC⁵, and these mutations have been shown to be associated with phosphorylation of extracellular signal-regulated kinase (ERK) and increased anchorage-independent cell growth activity¹⁵. These previous reports indicate the significance of HER2 mutations in CRC; however, numerous other HER2 mutations remain variants of unknown significance. Moreover, clinical NGS often detects multiple gene variants in a single patient^3,16, and these variants may interact with each other and affect cancer cell tumorigenesis. However, the interactions between gene variants are not fully understood.

In this study, we focused on a patient with CRC treated in our hospital whose HER2 G776S mutation (c.2326G > A, p.Gly776Ser) and an APC nonsense mutation were detected by clinical NGS. HER2 G776S is located in the tyrosine kinase domain in HER2 (amino acid 721–975). This domain has been found to have more frequent mutations compared with other domains^6,17. Several mutations such as A775_G776insYVMA and G776 > VC have been annotated as activating variants in non-small-cell lung carcinoma¹⁸. However, this G776S mutation is rare, and its significance is not fully understood. Here, we examined the oncogenic function and treatment sensitivity of the HER2 G776S mutation and assessed the interaction between the HER2 G776S mutation and loss of APC function.

Results

NGS-based multiplex gene assay for molecular profiling analysis and variant annotation in a CRC patient

The patient, a 57-year-old man, was diagnosed with colorectal adenocarcinoma with liver metastasis (Fig. 1A). After resection of the primary lesion, eight courses of chemotherapy with mFOLFOX6 plus cetuximab (anti-EGFR antibody) were performed. Subsequently, a right hepatic lobectomy was performed, but recurrence occurred in the liver, lung and brain, and the patient was referred to Kyoto University Hospital for clinical NGS examination.

As shown in Fig. 1B, three somatic mutations, HER2 G776S mutation, APC nonsense mutation, and TP53 missense mutation, were detected from his liver metastasis specimen by the NGS-based multiplex gene assay. Other mutations related to the HER2 signaling pathway (KRAS, NRAS, BRAF, and PIK3CA) were not detected. We also confirmed the HER2 G776S mutation in this specimen using Sanger sequencing (Fig. 1C). HER2 copy number amplification was not detected by real-time quantitative PCR (Supplementary Fig. 1).

According to the COSMIC database (v91; http://cancer.sanger.ac.uk/cosmic/), the amino acid position G776 is in the kinase domain of HER2, and several mutations in this region, such as G776 > VC, have been registered as oncogenic genes (Fig. 1D). G776S is a rare mutation that has been detected in three cases: two cases of gastric cancer and one case of urothelial tract cancer. However, its significance has not been elucidated.

Effect of HER2 G776S mutation on kinase activity and phosphorylation and its evaluation in classical cell-based transfection assays

We established plasmid expression vectors containing human cDNA encoding full-length HER2 wild-type (WT) (Supplementary Fig. 2A), mutant HER2 G776S, and G776 > VC as a positive control (Supplementary Fig. 2B). To evaluate the effect of HER2 G776S on kinase activity, we transiently transfected the HER2 WT or HER2 mutant expression vectors into HeLa cells, which do not have oncogenic variants in RTK-RAS-ERK pathway or Wnt/β-actin pathway. (Supplementary Table 1). We confirmed by immunoprecipitation that HER2 proteins were successfully generated in the transfected cells (Fig. 2A).

We measured their kinase activity toward peptide substrates. The kinase activity was significantly higher for HER2 G776S protein than WT protein but was less than that of HER2 G776 > VC (Fig. 2B). We assessed the phosphorylation of HER2 and EGFR, which is one of the dimerization partners of HER2, in WT-, G776S- and G776 > VC-transfected HeLa cells. As shown in Fig. 2C, G776S and G776 > VC transfection increased the phosphorylation of both HER2 and EGFR. However, similar to the results for kinase activity, the degree of HER2 and EGFR phosphorylation was weaker for G776S transfection than for G776 > VC transfection.

Next, we evaluated the oncogenic potential of HER2 G776S using classical cell-based transfection assay using murine cell lines, NIH/3T3 focus formation assay¹⁹, and Ba/F3 transformation assay^4,20. NIH/3T3 cells acquired the focus-forming ability by transfection with G776 > VC but not with G776S (Fig. 2D). Similarly, Ba/F3 cells exhibited IL3-independent proliferation upon transfection with G776 > VC but not G776S (Fig. 2E). These findings suggest that HER2 G776S had weaker phosphorylation capacity and kinase activity than the known HER2 mutation and did not promote the transformed phenotype in the transfection assays using murine cells.

Differences in the effects of HER2 G776S mutation on activation of the HER2 signaling pathway between APC-intact and APC-mutant cells

To assess the effect of the HER2 G776S mutation on the HER2 downstream signaling pathway in human cancer cells, we transfected HER2 WT or HER2 G776S expression vectors into several human cell lines: HeLa (cervical cancer cells), FHC (fetal human colon epithelial cells), CACO-2 (colorectal cancer cells) and COLO-320 cells (colorectal cancer cells). As described in the Methods section, these cell lines have no HER2 mutations or amplifications and no mutation in the HER2 downstream signals genes, KRAS, NRAS, BRAF or PIK3CA (Supplementary Table 1). HeLa and FHC cells are APC WT, and CACO-2 and COLO-320 harbor APC mutations. Using Western blotting, we consistently detected full-length APC in HeLa and FHC cells, and truncated APC in CACO-2 and COLO-320 cells (Fig. 3A). Using the TCF/LEF reporter assay, we confirmed that the Wnt activity was relatively higher in CACO-2 and COLO-320 cells than in the other two cell lines (HeLa and FHC cells) (Fig. 3B).

As shown in Fig. 3C, G776S transfection increased the amount of phosphorylated HER2 compared with WT transfection in all cell lines. Of note, G776S transfection increased the phosphorylation of the HER2 downstream signaling proteins, AKT and ERK1/2, in CACO-2 and COLO-320 cells (with mutant APC) but not in HeLa and FHC cells (with WT APC). Next, we established stably transfected FHC and COLO-320 cells and examined the effects of HER2 G776S transfection on cell proliferation and anchorage-independent cell growth activity. Transfection with HER2 WT or G776S did not affect cell proliferation in FHC or COLO-320 cells (Supplementary Fig. 3). By contrast, G776S transfection significantly increased anchorage-independent cell growth activity in COLO-320 cells (mutant APC) but not in FHC cells (WT APC). WT transfection did not alter anchorage-independent growth in either cell line (Fig. 3D).

Based on these findings, we hypothesize that the HER2 G776S mutation activates HER2 downstream signaling and acts as an oncogenic driver mutation in cells with APC mutations but is not sufficient to be oncogenic in cells with WT APC.

APC function interference in the effect of the HER2 G776S mutation on the HER2 signaling pathway activation

To evaluate the effects of loss of APC function on the HER2 signaling pathway, we used CRISPR-Cas9 to establish APC-KO cells. We tried to establish APC-KO cells using colon cell lines, such as FHC, but experienced difficulty because of the extremely poor infection efficiency of the lentivirus; therefore, we established APC-KO HeLa cells. As described in Supplementary Table 1, HeLa cells have no oncogenic variants in the RTK–RAS–ERK pathway or Wnt/β-actin pathway. As shown in Fig. 4A, we confirmed the loss of full-length APC protein in APC-KO cells. We used the TCF/LEF reporter assay to confirm that the Wnt/β-catenin signaling pathway was significantly activated in APC-KO cells compared with nontargeting control (NTC) cells (Fig. 4B).

To examine the effects of APC deficiency on the HER2 signaling pathway, we assessed the amount and phosphorylation of HER2 and downstream signal proteins, including detection of RAS–GTP (activated RAS), in APC-KO cells and NTC cells. APC KO significantly increased the amount of RAS–GTP (Fig. 4C) and slightly increased phosphorylated ERK 1/2 (Fig. 4A), whereas there was no apparent change in the amount or phosphorylation of other proteins of the HER2 signaling pathway (HER2, CRAF, MEK and AKT) (Fig. 4A and Supplementary Fig. 4A). These results suggest that APC KO increases RAS–GTP as well as the activity of the Wnt pathway without affecting phosphorylation of HER2 and other downstream signals.

To assess the effects of activation of the HER2 signaling pathway in G776S-transfected APC-KO cells, we next transiently transfected the HER2 WT or HER2 G776S expression plasmid vector into APC-KO and NTC cells. As shown in Fig. 3D, HER2 G776S transfection massively increased the phosphorylation of downstream proteins in the HER2 pathway, especially ERK1/2, in APC-KO cells. By contrast, G776S transfection did not affect AKT or ERK1/2 phosphorylation in NTC cells (Fig. 4D). G776S transfection and KO of APC synergistically increased RAS-GTP. (Interaction P < 0.01, two-way ANOVA) (Fig. 4E). Moreover, G776S transfection in APC-KO cells significantly increased anchorage-independent growth, whereas growth was not affected by mock or HER2 WT transfection in APC-KO cells (Fig. 4F).

We investigated the interaction between APC and HER2 G776S in CRC cells (COLO-320 cells). First, we transfected the APC WT expression plasmid vector (pCMV-Neo-Bam APC) into COLO-320 cells with an APC nonsense mutation. As shown in Fig. 5A, full-length APC was detected in APC WT-overexpressing COLO-320 cells along with the endogenous truncated APC protein. The activity of the Wnt/β-catenin signaling pathway was markedly reduced by the expression of exogenous APC (Fig. 5B). RAS–GTP signal activity was also significantly decreased (Fig. 5C), although the amounts and phosphorylation of other proteins in the HER2–RAS–ERK pathway were not altered by the expression of exogenous APC (Supplementary Fig. 4B).

Next, we cotransfected the APC WT expression vector with the HER2 WT or HER2 G776S expression vector into COLO-320 cells. HER2 G776S transfection increased the phosphorylation of AKT and ERK1/2 in cells without APC transfection, whereas their phosphorylation was not increased in cells with APC transfection (Fig. 5D). In COLO-320 cells, the amount of RAS–GTP was significantly increased by HER2 G776S transfection, but was not increased when APC was cotransfected (Fig. 5E).

To elucidate further the effect of Wnt/β-catenin pathway activity on RAS–GTP, we cultured COLO-320 cells with ICG-001, a Wnt pathway inhibitor that antagonizes β-catenin/TCF-mediated transcription²¹. As shown in Fig. 5F, ICG-001 dose-dependently suppressed Wnt pathway activity in COLO-320 (APC mutant) cells but did not change the amount of RAS–GTP (Fig. 5G). These results indicate that inhibition of transcription downstream of the Wnt pathway dose not suppress the amount of RAS–GTP.

Inhibition by afatinib of the proliferation and tumor growth of colon cancer cells harboring HER2 G776S and APC mutations

To investigate the efficacy of HER2-targeted therapy in colon cancer cells harboring HER2 G776S, we examined the effect of treatment with afatinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI). We investigated the cytotoxic effect of afatinib on COLO-320 cells (mutant APC) stably transfected with HER2 WT or HER2 G776S. Cells were also treated with gefitinib (EGFR TKI) for comparison. As shown in Fig. 6A, HER2 WT or G776S transfection increased EGFR and HER2 phosphorylation in COLO-320 cells, and afatinib inhibited both EGFR and HER2 phosphorylation. By contrast, gefitinib did not inhibit phosphorylation of either protein. Afatinib strongly suppressed AKT and ERK1/2 phosphorylation in HER2 G776S-transfected cells. Similarly, afatinib inhibited the cell viability of HER2 G776S-transfected COLO-320 cells compared with HER2 WT-transfected cells, but gefitinib did not alter their viability (Fig. 6B and Supplementary Fig. 5). In addition, as shown in Fig. 6C, afatinib significantly inhibited the anchorage-independent growth acquired by HER2 G776S transfection, but gefitinib did not. By contrast, gefitinib and afatinib did not alter the anchorage-independent growth of HER2 WT-transfected cells.

Next, we investigated the antitumor effects of afatinib using COLO-320 cells stably transfected with HER2 WT or HER2 G776S in a xenograft mouse model. HER2 G776S-transfected tumors showed no significant change in their growth speed compared with WT-transfected tumors (Fig. 6D); however, the tumors had an increased Ki-67 labeling index, which is a marker for the cell cycle and tumor growth (Fig. 6E,F). Afatinib did not inhibit the growth of WT-transfected tumors, but it significantly suppressed the growth of HER2 G776S-transfected tumors compared with the vehicle (DMSO) control group (Fig. 6D). Evaluation of the pathology revealed that HER2 G776S-transfected tumors treated with afatinib had a sparse cell density compared with those in the vehicle control group (Fig. 6E). We confirmed that Ki-67 expression was significantly suppressed by afatinib treatment in HER2 G776S-transfected xenograft tumors but not in HER2 WT-transfected tumors (Fig. 6F).

Discussion

In this study, we report on the function of the HER2 G776S mutation, which was detected in a patient with CRC who harbored an APC nonsense mutation. HER2 G776S transfection slightly increased the phosphorylation and kinase activity of HER2 but did not increase HER2 downstream signaling activity in cells with APC WT. We found that HER2 G776S increased the downstream signaling activity in cells with loss of APC function through an increase in the amount of RAS–GTP. We also found that afatinib, a pan-HER TKI, inhibited tumor growth of HER2 G776S-transfected COLO-320 cells with mutant APC.

Although most HER2 kinase domain mutations are categorized as activating^10,17, the kinase activity of HER2 G776S was weaker than that of G776 > VC and insufficient to activate downstream signaling. However, when accompanied by APC mutations, HER2 G776S activated downstream signaling and functioned as an oncogenic driver mutation. These results are consistent with previous reports showing that the activities of mutant HER2 are diverse and that some of these do not result in apparent oncogenic changes^12,22. The significance of these less active mutations is not clear, but they may acquire oncogenic potential through the coexistence of other genetic variants, such as APC mutations. APC mutations occur in more than 80% of CRCs²³, and may have a significant impact on the role and distribution of mutant HER2 in CRC. As far as we can find, there are three cases with HER2 G776S mutation in the COSMIC database (Fig. 1D), but these cases are not colorectal carcinoma and do not have APC mutation. However, we found all three cases had mutations of other genes (2, 4, and 10 genes, respectively) in the WNT/ β-catenin pathway-related gene set (KEGG_WNT_SIGNALING_PATHWAY) (Supplementary Table 2). We speculate that these cases may involve combined effects of the Wnt pathway and HER2 G776S mutation.

Although APC loss of function activates the Wnt pathway through the accumulation of β-catenin²⁴, our results show that loss of APC function increases the amount of activated RAS (RAS–GTP) as well as the activity of the Wnt pathway. This suggests the possibility of cross talk between the HER2–RAS–ERK pathway and the Wnt/β-catenin pathway. Our data are consistent with those of previous reports showing that APC and RAS mutations affect each other through interactions between these two pathways^25,26. In more recent studies, loss of APC function has been shown to stabilize the activated RAS, which results in increased function of the mutant RAS and leads to an early stage of colorectal carcinogenesis^27,28. Although little has been reported on the interaction between HER2 mutations and APC mutations, our findings suggest that the HER2 G776S mutation induces significant activation of the ERK pathway via the increase in activated RAS due to loss of APC function (Fig. 7). In our study, ICG-001, a β-catenin/TCF inhibitor, reduced Wnt activity but did not affect the amount of activated RAS (Fig. 5F,G). This result suggests that the crosstalk with RAS occurs upstream of β-catenin in the Wnt pathway and that suppression downstream of the Wnt pathway alone does not inhibit ERK signaling. Further detailed studies are needed to determine whether this crosstalk is directly dependent on APC mutations and whether the crosstalk effect differs depending on the type of APC mutations.

Next, we evaluated whether this HER2 mutation may be a therapeutic target in the treatment of CRC. In recent years, a variety of HER2-targeted therapies have attracted attention, including HER2 monoclonal antibodies, HER2 TKIs, and antibody–drug conjugates such as trastuzumab deruxtecan (T-DXd). Clinical trials have shown the efficacy of these therapies for treating in HER2-positive CRC. The HERACLES²⁹ and MyPathway³⁰ trials have investigated trastuzumab-based combination therapy for HER2-amplified CRC. The recently reported DESTINY-CRC01 trial³¹ showed the efficacy of T-DXd in HER2-expressing CRC. Although these trials did not evaluate HER2-mutated CRC directly, their results suggest that the various HER2-targeted therapies may be considered as future treatment strategies for HER2-mutated colorectal cancer. In this study, we examined the effect of treatment with afatinib, an irreversible pan-HER TKI, because it is expected to inhibit kinase activity increased by the G776S kinase domain mutation. Afatinib has been already approved by the US Food and Drug Administration for clinical use in non-small-cell lung carcinoma³² and has been reported to be effective in treating several cases of cancer with HER2 mutation³³.

To evaluate the effect of afatinib on CRC harboring HER2 G776S, we established xenografts with COLO-320, which include APC mutation. HER2 G776S transfection did not significantly increase tumor growth but increased the Ki-67 labeling index, a marker of cell cycle and tumor growth. Because COLO-320 cells are small and densely packed, and internal necrosis occurs as the tumor grows, there may have been little difference in the growth rate of the tumors. We found that afatinib was effective in suppressing the growth of xenograft tumors derived from HER2 G776S-transfected COLO-320 cells. This result suggests that HER2 G776S acted as a driver mutation in COLO-320 cells and that the cells were highly dependent on the mutated HER2 for xenograft formation. This patient was not treated with HER2-targeted therapy because the HER2 G776S mutation was not known to be oncogenic in advance. However, we believe that this study will help to provide a rationale for targeted therapy in future cases. If effective Wnt pathway inhibitors are developed in the future, combination therapy to hit both the Wnt and HER2 pathways may be worthwhile.

Our study has some limitations. First, cells were analyzed when expressing increased levels of the mutant HER2 and not endogenous levels. Analysis of overexpression is complicated because overexpression of HER2 itself causes some degree of transforming activity⁷. Therefore, we compared the transforming potential between HER2 mutants and HER2 WT whose expression levels were maintained at the same level using cell sorting and flow cytometry. Second, this study was conducted on a minor HER2 mutation observed in a single clinical case, and the findings may not contribute much to clinical medicine. However, clinical sequencing detects many rare mutations of unknown significance in practice. Each of them may have a small role in carcinogenesis but, as revealed in this study, some may be carcinogenic through synergistic effects and may be potential targets for therapy. We believe that our study provides information that will be relevant as clinical sequencing becomes more important in the choice of cancer treatment. Finally, the HER2 mutation in this study was detected in the liver metastases. We were not able to examine the genetic profile of the primary site because the primary surgery was performed at another hospital several years previously and the primary site tissue was not available. However, metastases have a similar mutational profile as the primary tumor³⁴^,³⁵, and we speculate that the gene profile in our study was not limited to metastatic tumors.

In conclusion, this study shows that the HER2 G776S mutation triggers HER2 downstream signaling activation when accompanied by APC loss of function and that this may be a potential therapeutic target in CRC. Our results suggest that the oncogenicity and potential targeting of HER2 mutations in CRC should be considered in the context of APC function. Our findings provide novel insights into HER2 functions and strategies to target them in CRC.

Methods

Clinical sequencing using an NGS-based multiplex gene assay

The formalin-fixed paraffin-embedded tumor tissue of the patient was submitted to EA Genomics (Morrisville, NC) to obtain the profile using an NGS-based multiplex gene assay (OncoPrime (3); Mitsui Knowledge Industry, Tokyo, Japan) covering 215 cancer-related genes (Supplementary Table 3).

Cell lines and investigation of their genetic features

HeLa cells were purchased from JCRB Cell Bank (Ibaraki, Japan), COLO-320 and Ba/F3 cells were purchased from Riken BioResource Center (Ibaraki, Japan), and FHC cells were purchased from ATCC (Manassas, VA). NIH/3T3 and CACO-2 cells were kindly provided by the Gastroenterology Department, Kyoto University, in April 2016. CACO-2 cells were validated using Short Tandem Repeat analysis by the Cell Line Authentication Service of Promega (Madison, WI) in March 2021. The composition of the medium for each cell is shown in Supplementary Table 4. All cells were cultured at 37 °C in a 5% CO₂ incubator.

The genetic features of the human cell lines, HeLa, CACO-2, and COLO-320 were examined using the database Cancer Cell Line Encyclopedia (https://portals.broadinstitute.org/ccle). Because FHC cells are not available in the database, we examined their genetic features by targeted NGS using the Ion AmpliSeq Comprehensive Cancer Panel (Thermo Fisher Scientific, Waltham, MA) in accordance with the manufacturer’s instructions. Variants of genes associated with the HER2 signaling pathway and Wnt/β-catenin pathway in the cell lines are shown in Supplementary Table 1. HER2 copy number changes were analyzed by quantitative polymerase chain reaction (PCR) using the qBiomarker Copy Number PCR Assay Kit (Qiagen, Hilden, Germany). HER2 primers (VPH117-0412044A) and reference primer set (VPH000-0000000A) were purchased from Qiagen.

Design and construction of the expression plasmid vectors

pDONR223-ERBB2³⁶, which is a plasmid vector harboring human HER2 cDNA, was a gift from William Hahn and David Root (Addgene plasmid #23888; http://n2t.net/addgene:23888; RRID:Addgene_23888). pCMV-Neo-Bam APC was a gift from Bert Vogelstein (Addgene plasmid # 16507; http://n2t.net/addgene:16507; RRID:Addgene_16507)²⁴.

We established plasmid expression vectors containing human cDNA encoding full-length HER2 wild-type (WT) and mutant HER2 G776S. In addition, an expression vector for mutant HER2 G776 > VC, a known driver mutation in lung cancer³⁷, was established as a positive control. To construct WT HER2 expression vectors, the coding sequence of HER2 cDNA was amplified by PCR using the pDONR223-ERBB2 as a template, and the PCR fragment was subcloned into the pcDNA3.1 vector (Thermo Fisher Scientific) using an In-Fusion HD Cloning Kit (Takara, Otsu, Japan). The resultant vectors are referred to as pcDNA_HER2-WT. To construct mutant HER2 expression vectors, HER2 G776S and HER2 G776 > VC were directly induced into the pcDNA_HER2 WT vector by site-directed mutagenesis using a PrimeSTAR Mutagenesis Basal Kit (Takara) with the mutagenic primers. The resultant vectors are referred to as pcDNA_HER2 G776S and pcDNA_HER2 G776 > VC. The sequences of oligo DNAs used for vector construction (PCR primers and mutagenic primers) are shown in Supplementary Table 5.

Transfection and establishment of stably transfected cells

The plasmids were transfected into cells using Lipofectamine LTX and Plus Reagent (Thermo Fisher Scientific) following the manufacturer’s instructions. Control cells were mock transfected with the same amount of the pcDNA or pCMV empty vector. Experiments using the transiently transfected cells were performed 48 h after transfection. To establish stably transfected cells with these plasmids, the transfected cells were cultured in 400 μg/mL hygromycin B (Nacalai Tesque, Kyoto, Japan) medium for 14–20 days. After drug selection, we aligned HER2 expression to the same level using cell sorting on a FACSAria III flow cytometer (BD Biosciences, Franklin Lakes, NJ) using allophycocyanin-conjugated anti-human HER2 antibody (Biolegend, San Diego, CA). Seven days after cell sorting, the experiments using stably transfected cells were performed.

Cell-based transfection assays using murine cell lines, NIH/3T3 and Ba/F3 cells

Focus formation assays were performed using NIH/3T3 cells stably transfected with pcDNA-mock, HER2- WT, G776S, or G776 > VC expression plasmid vectors. The cells (3 × 10⁵) were plated into 6 cm-diameter dishes and incubated in DMEM supplemented with 5% calf serum. Cells were fixed 12–14 days later and stained with a solution containing 30% methanol and 0.4% crystal violet. Foci larger than 1 mm in diameter were scored.

Ba/F3 transformation assay were performed using IL-3-dependent Ba/F3 cells stably transfected with the above plasmids. The cells (1 × 10⁵) were washed three times in PBS and seeded in complete medium without interleukin 3, and the number of viable cells was counted 5 days after seeding. Viability was determined by trypan blue exclusion.

Establishment of APC-knockout HeLa cells using the CRISPR-Cas9 system

APC knockout (KO) cells were generated using LentiCRISPR v2, which was a gift from Feng Zhang (Addgene plasmid #52961; http://n2t.net/addgene:52961; RRID:Addgene_52961)³⁸, following the manufacturer’s instructions. The sequences of single guide RNA (sgRNA) and oligos are listed in Supplementary Table 5. The sgRNA for APC KO was designed using GPP sgRNA Designer (https://portals.broadinstitute.org/gpp/public/). Cloning of the lentiCRISPR targeting APC was performed in the backbone of the all-in-one lentiCRISPR v2 vector, which contains the inserts Cas9 and the puromycin resistance marker. Forward and reverse oligos were mixed, annealed, and ligated with the BsmBI-digested lentiCRISPR backbone and transformed into Stbl3 chemically competent Escherichia coli (Invitrogen, Carlsbad, CA). Single bacterial colonies were selected and transferred to culture for the minipreparation of plasmids (QIAprep Spin Miniprep Kit; Qiagen). The established plasmids were verified by Sanger sequencing.

The resultant plasmids were transfected into HEK293T cells to produce viral particles using Trans-Lentiviral Packaging Kits (Horizon, Cambridge, UK) following the manufacturer’s instructions. HeLa cells (3 × 10⁵) were incubated in DMEM containing these viral particles and 10 μg/mL Polybrene. The plate was centrifuged at 1800 rpm at 32 °C for 1 h, and 2 days after the initial infection, the cells were refreshed with medium containing puromycin (1.0 μg/mL). After drug selection, single-cell colonies were isolated using cloning rings. Successful APC KO in clones was confirmed by Western blotting and TCF/LEF reporter assays.

Kinase activity assay of WT and mutant HER2 proteins

HeLa cells were transiently transfected with pcDNA-mock, HER2 WT, G776S, or G776 > VC as mentioned above and lysed with RIPA buffer (Nacalai Tesque) 48 h after transfection. Recombinant HER2 WT and mutant proteins in the lysate were purified by immunoprecipitation using Protein A Dynabeads (Thermo Fisher Scientific) and added rabbit monoclonal anti-HER2 (29D8) antibody (Cell Signaling Technology, Danvers, MA) following the manufacturer’s instructions.

The purified proteins were eluted into elution buffer under nondenaturing conditions and incubated with Poly-(4:1 Glu, Tyr) substrate peptide (Cosmo Bio, Tokyo, Japan) along with the kinase reaction mix from the ADPsensor Universal Kinase Activity Assay Kit (BioVision, Milpitas, CA) following the manufacturers’ instructions. The fluorescent signal was measured using an Infinite F200 PRO microplate reader (Tecan Group, Ltd., Männedorf, Switzerland).

Western blotting

The total cell lysate was extracted with lysis buffer, which is a mixture of RIPA buffer (Nacalai Tesque) and PhosSTOP phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO). Western blot analysis was performed as described previously³⁹. The antibodies and enhanced chemiluminescence solution are described in Supplementary Table 6. Full-length APC was detected with APC antibody (#2504) from Cell Signaling Technology, and truncated APC was detected with APC antibody (sc-9998) from Santa Cruz Biotechnology (Dallas, TX) raised against the N-terminus of APC. β-Actin was used as the loading control.

Soft agar colony-formation assay

Anchorage-independent cell growth activity was assessed using a soft agar colony-formation assay. Base layers of growth medium containing 1.0% low melting point agarose (Lonza, Basel, Switzerland) were poured into six-well plates and allowed to solidify. Cells (2.5 × 10⁴ per well) were plated in triplicate in the top layer comprising growth medium containing 0.67% agarose. In the treatment group, gefitinib (1.0 μM), afatinib (0.1 μM), or dimethyl sulfoxide (DMSO) vehicle (0.5%) was added to the cultures. Ten days after seeding, the plates were stained with crystal violet (Sigma-Aldrich) for 1 h. Colonies measuring > 50 μm were counted using a Biorevo BZ-9000 inverted microscope (Keyence, Osaka, Japan).

TCF/LEF activity assay

Wnt/β-catenin signaling activity was monitored using the TCF/LEF Reporter Kit (BPS Bioscience, San Diego, CA) following the manufacturer’s instructions. In brief, cells (1 × 10⁴/per well) were seeded into a 96-well plate. The next day, the TCF/LEF luciferase reporter vectors were transfected into cells, and the cells were incubated for 48 h. Cells were harvested, lysed, and analyzed using the Dual-Luciferase Reporter Assay System (Promega) to measure luciferase activity.

RAS–GTP assay

To examine RAS activity, we measured the amount of RAS–GTP from cell lysates using an RAS Activation G-LISA Kit (Cytoskeleton, Denver, CO) according to the manufacturer’s instruction. The signal was measured using an Infinite 200 PRO multiplate reader (Tecan Group Ltd.) at a wavelength of 490 nm. The results are expressed as the fold increase in activity compared with the control group.

Cell proliferation assay

Cell proliferation was quantified using a WST-1 assay (Roche Applied Science, Penzberg, Germany) according to the manufacturer’s instructions. Cells (1 × 10⁴ cells/well) were seeded into 96-well plates. All data were obtained using an Infinite 200 PRO multiplate reader (Tecan Group Ltd.) at a wavelength of 450 nm.

Xenograft models and in vivo afatinib treatment

Six-week-old BALB/cAJcl-nu/nu mice (CLEA Japan, Tokyo, Japan) were used for in vivo assays. To establish xenograft tumors derived from COLO-320 cells stably transfected with pcDNA-mock, HER2-WT, or HER2-G776S, each cell line (2 × 10⁶ cells) was suspended in 50% Matrigel (BD Biosciences) and injected subcutaneously into the flanks of the mice. Tumor volume was measured with calipers every 3 or 4 days and was calculated using the empirical formula: tumor volume = ½ × [(the shortest diameter)² × (the longest diameter)]. When the tumor volume was about 100 mm³, mice were randomly allocated to two groups (n = 6 in each group) that received either vehicle or 25 mg⁄kg afatinib orally by gavage once daily for 6 days per week. After 3 weeks of treatment, the mice were sacrificed, and the tumor pathology was evaluated. Ki-67-positive cells were scored by counting at least 1000 cells per low-power field under a Biorevo BZ-9000 light microscope (Keyence).

All animal experiments conformed to the relevant regulatory standards and were approved by the Institutional Animal Care and Use Committee of Kyoto University (Med Kyo 17253). Isoflurane (Fujifilm Wako pure chemical, Osaka, Japan) was used to anesthetize the mice. This study was conducted in accordance with the ARRIVE guidelines.

Statistics

All statistical analyses were performed using JMP 15 (SAS Institute Inc., Cary, NC). Two-tailed Student’s t tests were used to compare data between two groups, and One-way ANOVA and post-hoc Tukey Honest Significant Difference (HSD) tests were used to analyze three or more groups, unless otherwise indicated. The interaction between two factors was assessed using two-way ANOVA. Error bars represent ± SD. P < 0.05 was considered to be significant.

Ethics approval and consent to participate

This study has been approved by the research ethics committee of Kyoto University (G1182-1). Written informed consent was obtained from the patient for participation in this study. All methods were performed in accordance with the relevant guidelines and regulations.

Data availability

The sequencing data in this study have been deposited into the database of the DNA Data Bank of Japan (https://www.ddbj.nig.ac.jp/index-e.html) under accession number LC684105.

References

Biesecker, L. G. & Green, R. C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 371(12), 1170 (2014).
Google Scholar
Tsimberidou, A. M. et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: Validation and landmark analyses. Clin. Cancer Res. 20(18), 4827–4836 (2014).
Article CAS Google Scholar
Kou, T. et al. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 108(7), 1440–1446 (2017).
Article CAS Google Scholar
Jiang, J. et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65(19), 8968–8974 (2005).
Article CAS Google Scholar
Ross, J. S. et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 124(7), 1358–1373 (2018).
Article CAS Google Scholar
Loree, J. M. et al. Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. J. Natl. Cancer Inst. 110(12), 1409–1417 (2018).
Article Google Scholar
Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer. 5(5), 341–354 (2005).
Article CAS Google Scholar
Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109–119 (2012).
Article CAS Google Scholar
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
Article CAS Google Scholar
Connell, C. M. & Doherty, G. J. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2(5), e000279 (2017).
Article Google Scholar
Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554(7691), 189–194 (2018).
Article ADS CAS Google Scholar
Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3(2), 224–237 (2013).
Article CAS Google Scholar
Perera, S. A. et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. U S A. 106(2), 474–479 (2009).
Article ADS CAS Google Scholar
Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33(1), 125-36e3 (2018).
Article CAS Google Scholar
Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 5(8), 832–841 (2015).
Article CAS Google Scholar
Wheler, J. J. et al. Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res. 76(13), 3690–3701 (2016).
Article CAS Google Scholar
Lee, J. W. et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 12(1), 57–61 (2006).
Article CAS Google Scholar
Mar, N., Vredenburgh, J. J. & Wasser, J. S. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer 87(3), 220–225 (2015).
Article Google Scholar
Alvarez, A., Barisone, G. A. & Diaz, E. Focus formation: A cell-based assay to determine the oncogenic potential of a gene. J. Vis. Exp. 94, 51742 (2014).
Google Scholar
Warmuth, M., Kim, S., Gu, X. J., Xia, G. & Adrian, F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19(1), 55–60 (2007).
Article CAS Google Scholar
Eguchi, M., Nguyen, C., Lee, S. C. & Kahn, M. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med. Chem. 1(5), 467–472 (2005).
Article CAS Google Scholar
Zabransky, D. J. et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc. Natl. Acad. Sci. U S A. 112(45), E6205–E6214 (2015).
Article CAS Google Scholar
Markowitz, S. D. & Bertagnolli, M. M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361(25), 2449–2460 (2009).
Article CAS Google Scholar
Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275(5307), 1787–1790 (1997).
Article CAS Google Scholar
Yun, M. S., Kim, S. E., Jeon, S. H., Lee, J. S. & Choi, K. Y. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J. Cell Sci. 118(Pt 2), 313–322 (2005).
Article CAS Google Scholar
Park, K. S. et al. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J. Cell Sci. 119(Pt 5), 819–827 (2006).
Article CAS Google Scholar
Jeong, W. J. et al. Ras stabilization through aberrant activation of Wnt/beta-catenin signaling promotes intestinal tumorigenesis. Sci. Signal. 5(219), ra30 (2012).
Article Google Scholar
Jeong, W. J., Ro, E. J. & Choi, K. Y. Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway. Npj Precis. Oncol. 2, 1–10 (2018).
CAS Google Scholar
Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(6), 738–746 (2016).
Article CAS Google Scholar
Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20(4), 518–530 (2019).
Article CAS Google Scholar
Siena, S. et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial. Lancet Oncol. 22(6), 779–789 (2021).
Article CAS Google Scholar
Yang, J. C. et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16(2), 141–151 (2015).
Article CAS Google Scholar
Yamamoto, H. et al. Therapeutic potential of afatinib for cancers with ERBB2 (HER2) transmembrane domain mutations G660D and V659E. Oncologist. 23(2), 150–154 (2018).
Article CAS Google Scholar
Liu, G., Zhan, X., Dong, C. & Liu, L. Genomics alterations of metastatic and primary tissues across 15 cancer types. Sci. Rep. 7(1), 13262 (2017).
Article ADS Google Scholar
Patel, S. A., Rodrigues, P., Wesolowski, L. & Vanharanta, S. Genomic control of metastasis. Br. J. Cancer. 124(1), 3–12 (2021).
Article CAS Google Scholar
Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968–972 (2010).
Article ADS CAS Google Scholar
Shimamura, T. et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66(13), 6487–6491 (2006).
Article CAS Google Scholar
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods. 11(8), 783–784 (2014).
Article CAS Google Scholar
Ohashi, S. et al. Synthetic lethality with trifluridine/tipiracil and checkpoint kinase 1 inhibitor for esophageal squamous cell carcinoma. Mol. Cancer Ther. 19(6), 1363–1372 (2020).
Article CAS Google Scholar

Download references

Acknowledgements

This work was financially supported by Japan Society for the Promotion of Science KAKENHI (18H02692). The authors are grateful for technical assistance from the Center for Anatomical, Pathological and Forensic Medical Researches and the Medical Research Support Center, Kyoto University Graduate School of Medicine.

Author information

Authors and Affiliations

Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan
Yosuke Mitani, Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Ayaka Mizumoto, Yoshihiro Yamamoto, Tomoki Saito, Shigeki Kataoka, Junichi Matsubara, Atsushi Yamada, Masashi Kanai, Shigemi Matsumoto & Manabu Muto
DSK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan
Hiroaki Sakai
Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Keisui-kan, 97-1 Minami-hodate Kodo, Kyotanabe, Kyoto, W604610-0395, Japan
Kiyotsugu Yoshikawa
Department of Urology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Eijiro Nakamura

Authors

Yosuke Mitani
View author publications
You can also search for this author in PubMed Google Scholar
Shinya Ohashi
View author publications
You can also search for this author in PubMed Google Scholar
Osamu Kikuchi
View author publications
You can also search for this author in PubMed Google Scholar
Yukie Nakai
View author publications
You can also search for this author in PubMed Google Scholar
Tomomi Ida
View author publications
You can also search for this author in PubMed Google Scholar
Ayaka Mizumoto
View author publications
You can also search for this author in PubMed Google Scholar
Yoshihiro Yamamoto
View author publications
You can also search for this author in PubMed Google Scholar
Tomoki Saito
View author publications
You can also search for this author in PubMed Google Scholar
Shigeki Kataoka
View author publications
You can also search for this author in PubMed Google Scholar
Junichi Matsubara
View author publications
You can also search for this author in PubMed Google Scholar
Atsushi Yamada
View author publications
You can also search for this author in PubMed Google Scholar
Masashi Kanai
View author publications
You can also search for this author in PubMed Google Scholar
Shigemi Matsumoto
View author publications
You can also search for this author in PubMed Google Scholar
Hiroaki Sakai
View author publications
You can also search for this author in PubMed Google Scholar
Kiyotsugu Yoshikawa
View author publications
You can also search for this author in PubMed Google Scholar
Eijiro Nakamura
View author publications
You can also search for this author in PubMed Google Scholar
Manabu Muto
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Y.M., S.O. and M.M. wrote the manuscript and formatted figures. Y.M., O.K., Y.N., T.I. and Y.Y. were involved in conducting experiments and data analysis. A.M., T.S., S.K., J.M., A.Y., M.K. and S.M. participated in the design of the review and draft the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Manabu Muto.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Supplementary Information.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Mitani, Y., Ohashi, S., Kikuchi, O. et al. HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. Sci Rep 12, 9213 (2022). https://doi.org/10.1038/s41598-022-13189-y

Download citation

Received: 01 July 2021
Accepted: 04 May 2022
Published: 02 June 2022
DOI: https://doi.org/10.1038/s41598-022-13189-y

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.